Trailing Twelve Months Revenue Growth: Biomerica, Inc. (BMRA)

Niche patent protection for GI tests provides Biomerica, Inc. (BMRA) with a moderate advantage. The current sales growth rate over a rolling 12-month period year-over-year illustrates revenue dynamics, where -11.20 serves as the final level marker. Automation of dosing lines ensures production efficiency. However, regulatory costs associated with implementing gastroenterology systems render the company's free cash flow unstable.
Biomerica Inc. (BMRA) - metric breakdowns and financial figures

This indicator measures revenue dynamics over a rolling twelve-month period, neutralizing seasonality and market noise to determine the actual speed of business expansion. By analyzing the YoY revenue growth trend for TTM, an investor assesses the demand for Biomerica, Inc. (BMRA) diagnostic systems in clinics and pharmacies, where a steady ascent of the metric confirms the scaling of food intolerance test sales.